Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:chemicalFormula |
C20H25N3O2S
|
| gptkbp:hasCharacter |
Dopamine D2 receptor
5-HT2A receptor |
| gptkbp:hasCollaboratedWith |
academic institutions
research organizations |
| gptkbp:hasFilm |
dizziness
fatigue nausea |
| gptkbp:hasLocalCuisine |
Phase II
|
| gptkbp:hasMerchandise |
serotonin receptor modulation
|
| gptkbp:hasParticipatedIn |
treatment of neurological disorders
|
| gptkbp:hasWeight |
365.49 g/mol
|
| https://www.w3.org/2000/01/rdf-schema#label |
WME-970
|
| gptkbp:isAttendedBy |
oral tablet
excipients |
| gptkbp:isAvailableIn |
various dosages
|
| gptkbp:isAvenueFor |
pharmacokinetics
pharmacodynamics |
| gptkbp:isCitedIn |
research papers
|
| gptkbp:isConsidered |
combination therapy
|
| gptkbp:isDiscussedIn |
scientific literature
medical conferences |
| gptkbp:isEvaluatedBy |
peer review process
efficacy safety profile |
| gptkbp:isInformedBy |
binders
fillers |
| gptkbp:isMarketedAs |
brand name XYZ-970
|
| gptkbp:isPartOf |
clinical studies
placebo drug development pipeline therapeutic area standard treatments |
| gptkbp:isPortrayedBy |
clinical trial registries
|
| gptkbp:isRegulatedBy |
gptkb:FDA
EMA |
| gptkbp:isRelatedTo |
neurotransmitter systems
|
| gptkbp:isStudiedIn |
animal models
human trials |
| gptkbp:isSubjectTo |
clinical guidelines
patent law |
| gptkbp:isSuitableFor |
synthetic processes
|
| gptkbp:isUsedIn |
pharmaceutical research
|
| gptkbp:isUtilizedFor |
gptkb:schizophrenia
depression anxiety disorders |
| gptkbp:isVisitedBy |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:notableArtists |
chronic pain
bipolar disorder PTSD |
| gptkbp:numberOfFigures |
123456-78-9
|